Adrian Rawcliffe, Chief Executive Officer at Adaptimmune Therapeutics PLC (ADAP), sold 31,770 shares at $3.56 ($113K) on 2022-01-11, disclosed to the SEC on 2022-01-13.
Seasonal sale ($113k) by Chief Executive Officer — this insider has traded ADAP in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.56 | 14,362 | $51K | 45.2% |
| 2 | $3.56 | 14,362 | $51K | 45.2% |
| 3 | $3.54 | 3,046 | $11K | 9.5% |
| Total | $3.56 avg | 31,770 | $113K | 100% |
| Filing → |
| WVE | SELL | 2025-11-14 | $219K | — | Filing → |
| ADAP | SELL | 2025-01-17 | $18K | — | Filing → |
| ADAP | SELL | 2025-01-15 | $35K | — | Filing → |